References
- Murphy KR, Berger WE. The variability of asthma. Curr Med Res Opin 2005;21:1519–26
- Green RJ, Rens H. The hidden cost of asthma. S Afr Respir J 2004;10: 8–12
- Sivestri M, Sabatini F, Defilippi AC, Rossi GA. The wheezy infant immunological and molecular considerations. Paediatr Respir Rev 2004;5 Suppl A:S81–7
- Lin YZ, Haung FY. Infantile wheezing and bronchodilator treatment. Acta Paediatri Taiwan 2005;46:3–5
- Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332: 133–8
- Green RJ. Symptomatic treatment of upper respiratory tract symptoms in children. SA Family Practice 2006;48: 38–42
- Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ. Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol 2006;41: 577–83
- Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisone for viral wheeze in children aged 1–5 years: randomised controlled trial. Lancet 2003;362:1433–8
- Bisgaard H., Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006;354:1998–2005
- Haby MM, Powell CV, Oberklaid F, Waters EB, Robertson CF. Asthma in children: gaps between current management and best practice. Paediatr Child Health 2002;38:284–9
- Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist for the treatment of persistent asthma in children aged 2–5 years. Pediatrics 2001; 108: 1–10
- Bisgaard H, et al. Prevention of Viral-Induced Asthma. Montelukast in the Prevention of Exacerbations in Children Aged 25 Years with Asthma. Am J Respir Crit Care Med. 2005
- Sazonov Kocevar V, Jonsson L, Valovirta E, Thomas JIII, Kristensen F, Messonnier M, Bisgaard H. Inpatient cost among pediatric patients with asthma in four Nordic Countries. ECACI 2001 (abstract)